Latest California Healthline Stories

View More

Total Results: 7172

Mylan Hopes To Sell EpiPens Directly To Consumers And Bypass Pharmacies

Bloomberg reports on the company’s plans to expand its market and set up its own distribution network. In other health industry news, Walgreens’ CEO talks to analysts about plans for the merger with Rite Aid, a judge rules against Regeneron Pharmaceuticals and Sanofi on a patent dispute and traders are optimistic about biotech sector.

Mylan Could Benefit From New Push To Address Patient EpiPen Price Concerns

One solution to the EpiPen controversy, some advocates say, is classifying it as preventive care so consumers wouldn’t have to pay anything for the life-saving drug. But while the suggestions seems to favor consumers, a New York Times report finds Mylan is pulling the strings.

Law Would Limit Surprise Billing For Medical Care

The problem, known as balance billing, happens when patients are treated by an out-of-network professional at an in-network facility. Gov. Jerry Brown is expected to sign the legislation. In other news from Sacramento, regulators could learn lessons from Colorado if recreational marijuana use becomes legal in California.

EpiPen-Maker’s CEO To Face Congressional Fire At Hearing On Price Gouging

Chief Executive Heather Bresch will testify in front of the House Oversight and Government Reform Committee next week. Meanwhile, senators will introduce a bill requiring drugmakers to give a 30-day notice and justification of any prescription drug price increase of more than 10 percent. And The Associated Press examines pharmaceutical discount cards.